Hypertriglyceridemia - Epidemiology and Market Forecast-2028

Albany, NY -- (SBWire) -- 03/13/2019 --Hypertriglyceridemia - Epidemiology and Market Forecast-2028

12 Mar. 19

The most severe form of hypertriglyceridemia, lipoprotein lipase deficiency, occurs in approximately 1 case per 1 million.

1. The prevalence of hypertriglyceridemia in US adults aged 20 years and older was approximately 35% in men and 25% in women.
2. Hypertriglyceridemia is more common in men than in women.
3. Familial hypertriglyceridemia occurs in approximately 10% of men older than 30 years and women older than 60 years.
4. The Prevalence of very high hypertriglyceridemia is approximately 2 per 10,000 persons, with a greater prevalence in patients with diabetes.

(Albany, US) DelveInsight launched a new report on Hypertriglyceridemia - Market Insights, Epidemiology and Market Forecast-2028

Request for sample pages

Key topics covered

1. This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Hypertriglyceridemia market
2. Organize sales and marketing efforts by identifying the best opportunities for Hypertriglyceridemia market
3. To understand the future market competition in the Hypertriglyceridemia market.

"Hypertriglyceridemia is common among U.S. adults with an estimated prevalence of 33%. Among these, approximately 1.7% have severe hypertriglyceridemia, placing them at risk for pancreatitis."

In the current market scenario, the standard treatment for hypertriglyceridemia management includes fabric acid derivatives, niacin, and omega-3 fatty acids. High doses of strong statin also lower triglycerides, by as much as approximately 50%.

Therapeutic drugs such as fibric acid (gemfibrozil, fenofibrate, clofibrate), lipid-lowering agents (Niacin), lipid-lowering agents (simvastatin, atorvastatin, rosuvastatin) and omega-3 acids (icosapent ethyl, Omega3 fatty acids, Omega-3 carboxylic acids), lipid-lowering agents (Atorvastatin and Fluvastatin) are used in the treatment of Hypertriglyceridemia. Fibrates are currently the drugs of choice for hypertriglyceridemia, frequently in combination with statins. Niacin and omega-3 fatty acids improve control of triglyceride levels when the fibrates and statins are inadequately effective.

The other factors that shall further expedite the growth of hypertriglyceridemia market include increased morbidity rate of hypertriglyceridemia and increasing awareness about available treatments during the forecast period (2019-2028). A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for hypertriglyceridemia.

Companies covered

1. Arrow Head Pharma
2. Acasti Pharma
3. Regeneron Pharmaceuticals
4. AstraZeneca
5. Gemphire Therapeutics
And many others

Drugs covered

1. CaPre
2. Evinacumab
3. Epanova
4. Gemcabene
And many others

Table of contents

1. Report Introduction
2. Hypertriglyceridemia Market Overview at a Glance
3. Disease Background and Overview: Hypertriglyceridemia
4. Epidemiology and Patient Population
5. Epidemiology of Hypertriglyceridemia by Countries
5.1. United States
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.5. France
5.6. Italy
5.7. Spain
5.8. United Kingdom
5.9. Japan
7. Unmet Needs of the Hypertriglyceridemia
8. Marketed Therapies
8.1. Drug A: Company 1
8.2. Drug B: Company 2
9. Pipeline Therapies– At a glance
10. Key Cross Competition
11. Emerging Therapies for Hypertriglyceridemia
11.1. Drug C: Company 3
11.2. Drug D: Company 4
12. Hypertriglyceridemia: 7MM Market Analysis
13. Hypertriglyceridemia: Country-Wise Market Analysis
13.1. United States
13.2. EU-5
13.2.1. Germany
13.2.2. France
13.2.2.1. Market Size of Hypertriglyceridemia in France
13.2.2.2. Percentage Share of drugs marketed for Hypertriglyceridemia in France
13.2.2.3. Market Sales of Hypertriglyceridemia by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.3. Japan
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight